Forced expression of C/EBPα in BMMCs results in the dedifferentiation of BMMCs, recapitulating the characteristics of the ΔCF/ΔCF cells. (A) The results of the FACS analyses of mast cell (c-Kit and FcεRIα), myeloid cell (Ly6G/C and CD11b), macrophage (F4/80), basophil (CD49b), and eosinophil (Siglec-F) markers on BMMCs retrovirally transduced with either a control vector pMXs IG^40,41  or vector expressing C/EBPα cDNA by using a retroviral packaging cell line, PlatE.⁴²  Representative data from ≥5 independent analyses are shown. (B) The results of the Q-PCR analyses of transcription factors (upper) and cytokine receptors (lower) in the C/EBPα-expressing and control BMMCs. BMMCs were transfected with the pBAT12 IRES eGFP vector or pBAT12 Cebpa IRES eGFP by electroporation. The cell populations were sorted based on the intensity of GFP expression, as indicated. *P < .05; **P < .01 (compared with data from the vector-transfected cells). N = 4. (C) The results of the FACS analyses of mast cells (c-Kit and FcεRIα) and myeloid cells (Ly6G/C and CD11b) from ΔCF/ΔCF and ΔCF/ΔCF::Cebpa^−/− DKO BMMCs. The BMMCs were treated with 4-OHT for 9 days. The average percentages and SD of the DP and SP cells within the gates are shown. N = 4. (D) The results of the Q-PCR analyses of the indicated genes in wild-type, ΔCF/ΔCF, and DKO BMMCs after 9 days of 4-OHT treatment. *P < .05; **P < .01; ns, not significant (compared with data from wild-type cells). N = 4.